Comparing 1 or 2 weekly exercise classes for people receiving colorectal cancer treatment
Compares exercise classes held 1 or 2 days weekly in colorectal cancer treatment.
Plain-language title generated from the registry record
Registry title: Alberta Cancer Exercise Dose in Colorectal Cancer
Key facts
- Where
- Calgary, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Arthur J.E. Child Comprehensive Cancer Centre - Gastrointestinal tumour group outpatient clinicsCalgary, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Calgary
- Trial code
- NCT07913906
- Record updated
- 6 November 2026
- Original description
The purpose of this pilot randomized, wait-list controlled study is to evaluate the effects of exercise dose in terms of frequency (1 vs. 2 days per week) in individuals on systemic treatment for colorectal cancer. The impact on the individual (physical function, quality of life, fatigue and other patient reported outcomes) as well as on health care utilization (cost to deliver, cost to individuals, savings and impact to the health care system) will be evaluated. In addition, assessments of immunological markers to better understand the biological impact of exercise dose on immunological markers will be explored.Read full original descriptionShow less
Alberta Cancer Exercise Dose in Colorectal Cancer
The purpose of this pilot randomized, wait-list controlled study is to evaluate the effects of exercise dose in terms of frequency (1 vs. 2 days per week) in individuals on systemic treatment for colorectal cancer. The impact on the individual (physical function, quality of life, fatigue and other patient reported outcomes) as well as on health care utilization (cost to deliver, cost to individuals, savings and impact to the health care system) will be evaluated. In addition, assessments of immunological markers to better understand the biological impact of exercise dose on immunological markers will be explored.
Inclusion: Adults (≥18); Have a primary biopsy-proven diagnosis of colon or rectal adenocarcinoma and undergoing adjuvant systemic treatment; Cleared for exercise (PAR-Q+); Able to attend scheduled sessions; Able to provide informed written consent in English; Not meeting current aerobic exercise guidelines (i.e. performing < 90 minutes of moderate to vigorous physical activity per week in the past month).
Exclusion: Unstable cardiopulmonary disease; Uncontrolled hypertension; Active infection; Recent autoimmune flare; Participants who have completed adjuvant treatment for CRC; Contraindication to needles/venipuncture; Grade 2 or higher diarrhea secondary to systemic treatment.